GoodRx (NASDAQ:GDRX – Free Report) had its price target decreased by Truist Financial from $8.00 to $5.50 in a research report report published on Friday, Benzinga reports. Truist Financial currently has a hold rating on the stock.
Several other analysts have also issued reports on the stock. TD Cowen upgraded shares of GoodRx from a market perform rating to an outperform rating and raised their price target for the stock from $6.50 to $12.00 in a research report on Monday, July 31st. JPMorgan Chase & Co. increased their price objective on GoodRx from $6.00 to $7.00 and gave the company a neutral rating in a research report on Thursday, September 14th. Royal Bank of Canada reduced their price target on GoodRx from $8.00 to $5.00 and set a sector perform rating on the stock in a research report on Friday. DA Davidson upgraded GoodRx from a neutral rating to a buy rating and set a $9.50 target price on the stock in a report on Thursday, August 10th. Finally, The Goldman Sachs Group lowered their price objective on GoodRx from $7.00 to $6.00 and set a neutral rating on the stock in a research report on Friday. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $7.94.
GoodRx Price Performance
GoodRx (NASDAQ:GDRX – Get Free Report) last released its earnings results on Thursday, November 9th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.06. The company had revenue of $180.00 million during the quarter, compared to the consensus estimate of $188.52 million. GoodRx had a net margin of 2.04% and a return on equity of 2.28%. The company’s revenue was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.07 EPS. Equities analysts expect that GoodRx will post 0.08 EPS for the current year.
Institutional Investors Weigh In On GoodRx
Institutional investors and hedge funds have recently made changes to their positions in the business. Citigroup Inc. lifted its holdings in shares of GoodRx by 301.7% in the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock valued at $45,000 after buying an additional 6,006 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in GoodRx during the third quarter worth $201,000. Charles Schwab Investment Management Inc. raised its holdings in GoodRx by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 416,740 shares of the company’s stock worth $2,346,000 after purchasing an additional 26,832 shares during the last quarter. Swiss National Bank raised its holdings in GoodRx by 6.1% during the third quarter. Swiss National Bank now owns 164,500 shares of the company’s stock worth $926,000 after purchasing an additional 9,400 shares during the last quarter. Finally, Versor Investments LP raised its holdings in GoodRx by 139.2% during the third quarter. Versor Investments LP now owns 82,039 shares of the company’s stock worth $462,000 after purchasing an additional 47,739 shares during the last quarter. 33.63% of the stock is owned by hedge funds and other institutional investors.
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
- Five stocks we like better than GoodRx
- What Does the Consumer Price Index Measure?
- MarketBeat Week in Review – 11/6 – 11/10
- Growth Stocks: What They Are, Examples and How to Invest
- Data giants MongoDB and Snowflake just got upgraded
- What is Insider Trading? What You Can Learn from Insider Trading
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.